SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X Shares

A rebound in biotech stocks is driving LABU higher, with traders tracking the sectors move through XBI and positioning around upcoming inflation data that could affect rate-sensitive biotech shares. The community is split between expecting the bounce to continue and cautioning that LABUs 3x leverage can magnify pullbacks.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires quarterly results and stepped-up share repurchases are driving discussion: some traders view the buybacks as a vote of confidence from Greg Abel, while others focus on weaker insurance performance and question whether repurchases can continue.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,366,684,616.305855 in circulation. The last known price of Stellar is 0.15346137 USD and is down -1.11 over the last 24 hours. It is currently trading on 848 active market(s) with $109,670,947.94 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLMs persistent selloff and underperformance dominate discussion, with traders warning of further losses while others treat the decline as a buying opportunity. Bulls point to Stellars tokenization and institutional-adoption prospects, including DTCC-related plans, but skeptics argue that partnerships have not translated into token demand and question the tokenomics.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is drawing attention as traders question whether enterprise AI projects will translate into sustained consulting revenue or instead reduce billable work and pressure margins. The debate is playing out against a sharp rally and technical resistance, with bearish traders watching for a pullback and bulls pointing to insider buying and continued demand for AI implementation.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Attention centers on long-term lorundrostat data reporting that blood-pressure benefits persisted for two years after treatment ended, alongside the upcoming FDA decision on the hypertension drug. Traders view the durability findings as encouraging but remain divided amid the stocks weakness and the binary regulatory catalyst.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Foxs acquisition of Roku has closed, ending ROKUs run as a standalone Nasdaq-listed company and shifting holders into the deals cash-and-Fox-stock consideration. The community is marking the end of the ticker with a mix of congratulations and disappointment that the sale capped Rokus potential, while some traders are also discussing bullish call activity.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

A Nasdaq and technology-sector selloff is weighing on JEPQ, prompting traders to compare its decline with the broader tech pullback. Many are buying the dip for monthly income, while others question whether distributions offset the funds price weakness and limited upside from its covered-call strategy.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus is drawing attention for the potential of its ITK inhibitor soquelitinib across several clinical indications, with traders watching for trial updates and possible partnerships. Optimists point to the science and reported institutional or insider buying, while skeptics focus on delayed data, the long path to revenue, and persistent short interest.

Invesco DB US Dollar Index Bullish Fund - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

A rebound in the U.S. dollar, with traders watching payrolls data and the Fed rate outlook, is the main focus for UUP. Some see continued dollar strength as a headwind for stocks and precious metals, while others question whether the move will last.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroups quarterly earnings dominate discussion: the bank beat expectations, yet shares fell, leaving traders debating whether higher credit-loss provisions and card-business pressure outweighed stronger results. Some view the selloff as an opportunity, while others remain concerned about costs and credit quality.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why

KALA Bio shares surge after hours after signing an LOI to acquire a nationwide telehealth platform.read more...

These Stocks are Charging Higher as Traders Watch What Comes Next

The following are showing notable momentum today, with Kraig Biocraft Laboratories (OTCQB:KBLB), Iovance Biotherapeutics (NASDAQ:IOVA), Volato Group (NYSEAMERICAN:SOAR), Carnival Corporation (NYSE:CCL), Teads Holding (NASDAQ:TEAD), Quantum-Si (NASDAQ:QSI), and KALA Bio (NASDAQ:KALA) all posting gains and holding their moves as traders look toward the afternoon and tomorrow.

KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark

Equity

Kala Bio said it will implement a 1-for-50 reverse stock split, effective after the closing bell on May 8.

KALA BIO (NASDAQ:KALA) Posts Quarterly Earnings Results

KALA BIO (NASDAQ:KALA - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.86 earnings per share (EPS) for the quarter...

KALA BIO, Inc. (NASDAQ:KALA) Sees Significant Drop in Short Interest

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) was the target of a large drop in short interest in March. As of March 31st, there was short interest totaling 1,137,572 shares, a drop of 83.3% from...

KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of "Hold" from Analysts

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, MarketBeat.com reports. One equities research...

KALA BIO, Inc. (NASDAQ:KALA) Short Interest Up 600.0% in March

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 6,830,724 shares...

KALA BIO (KALA) Projected to Post Quarterly Earnings on Thursday

KALA BIO (NASDAQ:KALA) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...

KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) saw a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 975,765 shares, a growth...

AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle. $KALA, $TGNT, $DOMO, $TSSI, $CYN, $AUNA, $VACHU

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Bio Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>The company’s outstanding shares will be reduced from roughly 929.5 million to around 18.6 million shares.</li><li>Kala Bio had until July 20, 2026, to regain compliance with Nasdaq’s minimum price requirement of $1 per share.</li><li>The Board of Directors had the option to effect a reverse stock split in a ratio ranging from 1-for-2 to 1-for-100.&nbsp;</li></ul>Shares of Kala Bio (KALA) plunged more than 27% to a record low on Thursday after the company announced a reverse stock split, following months of relentless decline that kept the stock from reclaiming the crucial $1 threshold even once this year.Kala Bio said it will implement a 1-for-50 reverse stock split, effective after the closing bell on May 8. The stock will begin trading on a split-adjusted basis on Nasdaq from May 11.Following the move, the company’s outstanding shares will be reduced from roughly 929.5 million to around 18.6 million shares.<h2 class="st-heading-2">KALA Shares Fell Below $1 In December 2025</h2>Kala Bio has until July 20, 2026, to regain compliance with Nasdaq’s minimum price requirement of $1 per share. It had received a notice from the exchange in January for failing to trade above the threshold for 30 straight business days between Dec. 3, 2025, and Jan. 16, 2026.Following the notice, the company held a special stockholder meeting on January 30, at which shareholders approved the Board of Directors’ authorization to effect a reverse stock split at a ratio of 1-for-2 to 1-for-100.<h2 class="st-heading-2">Retail Urges Buying The Dip</h2>Despite the intraday slump, retail sentiment on Stocktwits changed to ‘neutral’ from ‘bearish’ a day earlier.Chatter was largely positive, with one user stating that they would buy more shares.<stembedurl>https://stocktwits.com/7traderja/message/652575680</stembedurl><a href="https://stocktwits.com/symbol/KALA">KALA shares</a> have plummeted 86% so far this year.<h2 class="st-heading-2">‘Palantir For Biotech’</h2>Earlier this year, the company <a href="https://stocktwits.com/news-articles/markets/equity/why-did-kala-stock-surge-in-pre-market-today/cZdAxnCRIJk">unveiled</a> the Researgency.ai platform designed for biotech and pharmaceutical companies to help automate research and drug development tasks.It can support clinical trials, regulatory document management, drug safety tracking, and commercial launch preparation, the company said.“We are building the Palantir for biotech,” CEO Avi Minkowitz stated.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/atara-atra-stock-rises-fda-meeting-cancer-treatment/cZXbLfKReQ7">ATRA Stock Sees Biggest Single-Day Gain In Over 2 Years, Breaches Key Technical Milestone – New FDA Update Has Bulls Circling Back</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

KALA BIO Inc

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Ticker SCAG had huge news, could go parabolic:       
       
Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group       
       
SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀     
 
$KALA $SPY $QQQ $HIHO hs

$KALA 
I like this stock 
Will buy again post split 
This split should clear all mess Imo

$KALA man, this group is dead. Maybe if there were some more engagement could build some excitement here. They do have an upside with this telehealth acquisition. It's not all gloom and doom.

Frank Mars

$KALA is asking shareholders to approve a reverse split ranging from 1-for-2 to 1-for-300 at its November 3, 2026, meeting at 10 a.m. Eastern. If approved, the board chooses the exact ratio and timing.

$KALA  how much time do they have left; split in May, delisting notice in August, and is asking shareholders to approve another split at Nov meeting

Feed

News

Sentiment

Earnings

Fundamentals

Info

KALA KALA BIO Inc

Fundamentals

Latest KALA News